CD16三价双特异性抗体的抗肿瘤作用的开题报告.docxVIP

抗ErbB2/CD16三价双特异性抗体的抗肿瘤作用的开题报告

摘要：

ErbB2是一种细胞表面受体，在多种恶性肿瘤中过度表达。因此，抑制ErbB2信号通路已成为治疗肿瘤的重要策略。抗ErbB2单克隆抗体（mAb）已被成功地用于治疗ErbB2阳性的乳腺癌和胃癌。但是，抗ErbB2mAb也存在一些局限性，如耐药性和免疫细胞的免疫抑制作用。因此，近年来双特异性抗体（BsAb）的研究受到了越来越多的关注。

本文介绍了一种针对ErbB2/CD16的三价双特异性抗体（tri-specificAb），它能够同时结合ErbB2和CD16，从而激活免疫细胞的作用，增强瘤细胞的杀伤效应。与抗ErbB2mAb相比，这种BsAb在细胞毒性方面表现更强，可以对付一些对单抗耐药的肿瘤细胞株。同时，该BsAb还能够抑制Treg细胞的免疫抑制作用，增强CD8+T细胞的杀伤作用，从而实现更好的治疗效果。

本文所述的tri-specificAb，已经完成了体外实验和动物试验阶段，虽然仍需更进一步的研究，但它有望成为一种新的治疗肿瘤的治疗方法。

关键词：ErbB2，CD16，双特异性抗体，肿瘤治疗

Abstract:

ErbB2isacellsurfacereceptorthatisoverexpressedinseveralmalignancies.Therefore,inhibitingtheErbB2signalingpathwayhasbecomeanimportantstrategyfortreatingtumors.Anti-ErbB2monoclonalantibodies(mAbs)havebeensuccessfullyusedtotreatErbB2-positivebreastandgastriccancers.However,anti-ErbB2mAbsalsohavesomelimitations,suchasresistanceandimmunesuppressionofimmunecells.Therefore,inrecentyears,researchonbispecificantibodies(BsAbs)hasreceivedincreasingattention.

Thispaperintroducesatri-specificantibody(tri-specificAb)againstErbB2/CD16,whichcansimultaneouslybindtoErbB2andCD16,therebyactivatingtheimmunefunctionofimmunecellsandenhancingthekillingeffectoftumorcells.Comparedwithanti-ErbB2mAbs,thisBsAbhasastrongercytotoxicityandcancopewithsometumorcelllinesresistanttomonoclonalantibodies.Atthesametime,theBsAbcanalsoinhibittheimmunosuppressiveeffectofTregcellsandenhancethekillingeffectofCD8+Tcells,therebyachievingabettertherapeuticeffect.

Thetri-specificAbdescribedinthispaperhascompletedinvitroexperimentsandanimaltrials.Althoughfurtherresearchisstillneeded,itisexpectedtobecomeanewtherapeuticmethodfortreatingtumors.

Keywords:ErbB2,CD16,bispecificantibodies,tumortherapy